Zealand Pharma A/S (ZLDPF) Projected to Post Quarterly Earnings on Thursday

Zealand Pharma A/S (OTCMKTS:ZLDPF) will likely be issuing its results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.3651) per share and revenue of $2.8120 million for the quarter.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a return on equity of 48.10% and a net margin of 70.06%.The firm had revenue of $10.79 million for the quarter, compared to the consensus estimate of $19.69 million. On average, analysts expect Zealand Pharma A/S to post $3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zealand Pharma A/S Price Performance

Shares of ZLDPF remained flat at $45.30 during midday trading on Tuesday. The company’s stock had a trading volume of 4,070 shares, compared to its average volume of 1,906. The firm has a fifty day moving average of $47.19 and a 200 day moving average of $63.40. Zealand Pharma A/S has a 1 year low of $35.93 and a 1 year high of $83.12. The firm has a market capitalization of $3.24 billion, a price-to-earnings ratio of 3.31 and a beta of 0.87. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. BNP Paribas Exane downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 6th. Finally, William Blair reaffirmed a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Zealand Pharma A/S currently has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark?based biopharmaceutical company specializing in the discovery, design and development of peptide?based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.